Increases in calorie consumption and sedentary lifestyles are fuelling a global pandemic of
cardiometabolic diseases, including coronary artery disease, diabetes mellitus …

Acute decompensated heart failure (ADHF) is one of the leading admission diagnoses
worldwide, yet it is an entity with incompletely understood pathophysiology and limited …

The quantification of protein biomarkers in blood at picomolar-level sensitivity requires
labour-intensive incubation and washing steps. Sensing proteins in sweat, which would …

Aims Differences in clinical characteristics and outcome of patients with established heart
failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection …

Heart failure (HF) describes a heterogenous complex spectrum of pathological conditions
that results in structural and functional remodeling leading to subsequent impairment of …

In recent years, GLP-1 receptor agonists (GLP-1RA), and SGLT-2 inhibitors (SGLT-2i) have
become available, which have become valuable additions to therapy for type 2 diabetes as …

A fine balance between uptake, storage, and the use of high energy fuels, like lipids, is
crucial in the homeostasis of different metabolic tissues. Nowhere is this balance more …

Heart failure (HF) with preserved ejection fraction (HFpEF) is currently the predominant form
of HF with a dramatic increase in risk with age. Low‐grade inflammation, as occurs with …

Heart failure is an epidemic disease which affects about 1% to 2% of the population
worldwide. Both, the etiology and phenotype of heart failure differ largely. Following a …

For decades, heart failure with preserved ejection fraction (HFpEF) proved an elusive entity
to treat. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently been shown to …